| Filed On | Filing |
|---|---|
| 31 Jan 2024 |
8-K/A: Regulation FD Disclosure
January 2024 We Are the Optejet® Company Developing and commercializing ophthalmic drug - device therapeutics with Optecare Ρ services in large markets with high unmet needs EYEN - COM - V2 - 0021 |
| 09 Mar 2022 | 8-K/A: Entry into a Material Definitive Agreement; Other Events |
Loading...
